Multiple myeloma

Seminars in Musculoskeletal Radiology

Volumn 13, Issue 2, 2009, Pages 111-119

  Baur Melnyk, Andrea ^a   Reiser, Maximilian F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

MDCT; MRI; Multiple myeloma; Whole body imaging

Indexed keywords

CONTRAST MEDIUM; CORTISONE; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

BONE DESTRUCTION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; COMPRESSION FRACTURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; HUMAN; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE MYELOMA; PLASMACYTOMA; PROGNOSIS; REMISSION; REVIEW; SKELETON RADIOGRAPHY; TREATMENT RESPONSE; WHOLE BODY MRI;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIPLE MYELOMA; NEOPLASM STAGING; OSTEOPOROSIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; WHOLE BODY IMAGING;

EID: 67649362491     PISSN: 10897860     EISSN: 1098898X     Source Type: Journal    
DOI: 10.1055/s-0029-1220882     Document Type: Review

References (29)

1. Durie BGM, Kyle RA, Belch A, et al; Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4(6):379-398
2. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842-854
3. Hall FM, Gore SM. Osteosclerotic myeloma variants. Skeletal Radiol 1988;17(2):101-105 (Pubitemid 18080662)
4. Mahnken AH, Wildberger JE, Gehbauer G, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002;178(6):1429-1436 (Pubitemid 34547826)
5. Baur-Melnyk A, Buhmann S, Dürr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005;55:56-64 (Pubitemid 40798488)
6. Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008;190(4):1097-1104 (Pubitemid 351571514)
7. Stäbler A, Baur A, Bartl R, Munker R, Lamerz R, Reiser M. Contrast enhancement and quantitative signal analysis in MRI of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol 1996;167:1029-1036 (Pubitemid 26322270)
8. Rahmouni A, Divine M, Mathieu D, et al. Detection of multiple myeloma involving the spine: efficacy of fat suppression and contrast-enhanced MRI. AJR Am J Roentgenol 1993;160:1049-1052 (Pubitemid 23141248)
9. Baur A, Bartl R, Pellengahr C, Baltin V, Reiser MF. Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings. Cancer 2004;101(11):2599-2604 (Pubitemid 39532290)
10. Tertti R, Alanen A, Remes K. The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol 1995;91:658-660
11. Lecouvet FE, Malghem J, Michaux L, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106(1):35-39 (Pubitemid 29343524)
12. Van de Berg BC, Lecouvet FE, Michaux L, et al. Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. Radiology 1996;201(1):243-246 (Pubitemid 26314395)
13. Dimopoulos MA, Moulopoulos A, Smith TL, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993;94(1):57-61 (Pubitemid 23021172)
14. Baur A, Staebler A, Nagel D, Lamerz R, Bartl R, Hiller E, Wendtner C, Bachner F, Reiser M. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon. Cancer 2002;95:1334-1345 (Pubitemid 35013070)
15. Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using F18-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:361-366 (Pubitemid 34253248)
16. Durie BGM, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43(11):1457-1463
17. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission computer tomography, magnetic resonance imaging and whole body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007;92:50-55 (Pubitemid 46232657)
18. Fonti R, Salvatore B, Quarantelli M, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008;49(2):195-200 (Pubitemid 351225656)
19. Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995;13(1):251-256
20. Dimopoulos MA, Moulopoulos A, Smith TL, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993;94(1):57-61 (Pubitemid 23021172)
21. Kusumoto S, Jinnai I, Itoh K, et al. Magnetic resonance imaging patterns in patients with multiple myeloma. Br J Haematol 1997;99:649-655 (Pubitemid 27519869)
22. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007;25(9):1121-1128 (Pubitemid 46596765)
23. Hillengass J, Wasser K, Delorme S, et al. Lumbar bone marrow microcirculation measurements from dynamic contrast- enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res 2007;13(2 Pt 1):475-481 (Pubitemid 46225352)
24. Singh J, Fairbairn KJ, Williams C, Das-Gupta EP, Russell NH, Byrne JL. Expert radiological review of skeletal surveys identifies additional abnormalities in 23% of cases: further evidence for the value of myeloma multi-disciplinary teams in the accurate staging and treatment of myeloma patients. Br J Haematol 2007;137:172-173 (Pubitemid 46474714)
25. Horger M, Kanz L, Denecke B, et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007;109(8):1617-1626 (Pubitemid 46595698)
26. Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiology 1994;193(2):441-446 (Pubitemid 24338331)
27. Rahmouni A, Divine M, Mathieu D, et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol 1993;16:1053-1057 (Pubitemid 23141249)
28. Carlson K, Aström G, Nyman R, Ahlström H, Simonsson B. MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment. Acta Radiol 1995;36(1):9-14
29. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDGPET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005;184(4):1199-1204 (Pubitemid 43821897)